<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044693</url>
  </required_header>
  <id_info>
    <org_study_id>091252</org_study_id>
    <nct_id>NCT01044693</nct_id>
  </id_info>
  <brief_title>Nebivolol in the Supine Hypertension of Autonomic Failure</brief_title>
  <official_title>Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of the antihypertensive drug, nebivolol
      (Bystolic), compared to metoprolol (Lopressor) and sildenafil (Viagra) on blood pressure in
      patients with autonomic failure and supine hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nebivolol is distinct among beta-blockers by its ability to increase nitric oxide (NO)
      bioactivity. The contribution of this effect to the pharmacological actions of the drug,
      however, is difficult to ascertain in normal subjects because of the confounding contribution
      of the autonomic nervous system. Autonomic failure patients provide a unique model of
      hypertension devoid of autonomic modulation but sensitive to NO mechanisms. We propose to
      determine the effect of nebivolol on blood pressure in this patient population. A decrease in
      blood pressure will imply increased bioactivity of NO. Comparisons will be made with placebo,
      metoprolol (as a negative control) and sildenafil (as a positive control).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure During the Night</measure>
    <time_frame>8 pm - 8 am</time_frame>
    <description>Maximal change from baseline in systolic blood pressure, measured from 8 pm to 8 am, after a single dose of the intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nocturnal Urinary Sodium Excretion</measure>
    <time_frame>8 pm - 8 am</time_frame>
    <description>Nocturnal sodium excretion was defined as the ratio of urinary sodium to urinary creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthostatic Tolerance the Following Morning</measure>
    <time_frame>10 min standing</time_frame>
    <description>Orthostatic tolerance was defined as the area under the curve of standing systolic blood pressure calculated by the trapezoidal rule (upright systolic blood pressure multiplied by standing time) during a 10-minute standing test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate During the Night</measure>
    <time_frame>8 pm - 8 am</time_frame>
    <description>Change from baseline (8 pm) in heart rate at the time of maximal BP-lowering effect</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypertension</condition>
  <condition>Pure Autonomic Failure</condition>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebivolol 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebivolol 5 mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol tartrate 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol tartrate 50 mg single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil 25 mg single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo capsule</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol 5 mg</intervention_name>
    <description>Nebivolol 5mg single oral dose</description>
    <arm_group_label>Nebivolol 5 mg</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol tartrate 50 mg</intervention_name>
    <description>metoprolol tartrate 50 mg single oral dose</description>
    <arm_group_label>Metoprolol tartrate 50 mg</arm_group_label>
    <other_name>Lopressor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil25 mg</intervention_name>
    <description>Sildenafil 25 mg single oral dose</description>
    <arm_group_label>Sildenafil 25 mg</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female and aged 18 years or over.

          -  Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic
             Failure (Parkinson Disease, Multiple System Atrophy and Pure Autonomic Failure).

          -  A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic
             blood pressure of at least 10 mmHg, within 3 minutes after standing.

          -  Supine hypertension, defined as a systolic blood pressure &gt;150 mm Hg or diastolic
             blood pressure &gt; 90 mm Hg.

          -  Provide written informed consent to participate in the study and understand that they
             may withdraw their consent at any time without prejudice to their future medical care.

        Exclusion Criteria:

          -  Have changed dose, frequency and or type of prescribed medication, within two weeks of
             study start.

          -  Women of childbearing potential who are not using a medically accepted contraception.

          -  Have, in the investigator's opinion, any significant cardiac, systemic, hepatic, or
             renal illness.

          -  Diabetes mellitus or insipidus.

          -  In the investigator's opinion, have clinically significant abnormalities on clinical
             examination or laboratory testing.

          -  In the investigator's opinion, are unable to adequately co-operate because of
             individual or family situation.

          -  In the investigator's opinion, are suffering from a mental disorder that interferes
             with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major
             depression, dementia.

          -  Are not able or willing to comply with the study requirements for the duration of the
             study.

          -  Persons on drugs with beta-blocking potential (e.g., amiodarone), persons taking
             scheduled or as needed nitrates and persons on drugs with alpha-blocking potential
             (e.g. tamsulosin).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mc.vanderbilt.edu/gcrc/adc</url>
    <description>Autonomic Dysfunction Center. Vanderbilt University</description>
  </link>
  <reference>
    <citation>Biaggioni I, Garcia F, Inagami T, Haile V. Hyporeninemic normoaldosteronism in severe autonomic failure. J Clin Endocrinol Metab. 1993 Mar;76(3):580-6.</citation>
    <PMID>7680352</PMID>
  </reference>
  <reference>
    <citation>Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995 Sep;274(3):1067-71.</citation>
    <PMID>7562470</PMID>
  </reference>
  <reference>
    <citation>Gamboa A, Shibao C, Diedrich A, Paranjape SY, Farley G, Christman B, Raj SR, Robertson D, Biaggioni I. Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure. Hypertension. 2008 Jun;51(6):1531-6. doi: 10.1161/HYPERTENSIONAHA.107.105171. Epub 2008 Apr 21.</citation>
    <PMID>18426998</PMID>
  </reference>
  <reference>
    <citation>Gupta S, Wright HM. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther. 2008 Fall;26(3):189-202. doi: 10.1111/j.1755-5922.2008.00054.x. Review.</citation>
    <PMID>18786089</PMID>
  </reference>
  <reference>
    <citation>Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic failure and its treatment. Hypertension. 1997 Nov;30(5):1062-7.</citation>
    <PMID>9369256</PMID>
  </reference>
  <reference>
    <citation>Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001 Jul 31;104(5):511-4.</citation>
    <PMID>11479245</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2010</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <results_first_submitted>April 14, 2015</results_first_submitted>
  <results_first_submitted_qc>April 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 1, 2015</results_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>supine Hypertension</keyword>
  <keyword>autonomic failure</keyword>
  <keyword>nitric oxide</keyword>
  <keyword>nebivolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Then Metoprolol Then Sildenafil Then Nebivolol</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Nebivolol Then Metoprolol Then Sildenafil</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P3">
          <title>Placebo Then Sildenafil Then Nebivolol Then Metoprolol</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P4">
          <title>Placebo Then Sildenafil Then Metoprolol Then Nebivolol</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P5">
          <title>Nebivolol Then Placebo Then Metoprolol Then Sildenafil</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P6">
          <title>Metoprolol Then Sildenafil Then Placebo Then Nebivolol</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P7">
          <title>Sildenafil Then Nebivolol Then Placebo Then Metoprolol</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P8">
          <title>Metoprolol Then Placebo Then Nebivolol Then Sildenafil</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P9">
          <title>Nebivolol Then Metoprolol Then Sildenafil Then Placebo</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P10">
          <title>Metoprolol Then Nebivolol Then Placebo Then Sildenafil</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P11">
          <title>Metoprolol Then Sildenafil Then Nebivolol Then Placebo</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P12">
          <title>Sildenafil Then Nebivolol Then Metoprolol Then Placebo</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P13">
          <title>Sildenafil Then Metoprolol Then Nebivolol Then Placebo</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P14">
          <title>Nebivolol Then Sildenafil Then Metoprolol Then Placebo</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P15">
          <title>Nebivolol Then Placebo Then Sildenafil Then Metoprolol</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
        <group group_id="P16">
          <title>Placebo Then Nebivolol Then Sildenafil Then Metoprolol</title>
          <description>Single oral dose of: metoprolol tartrate 50 mg, sildenafil 25 mg, nebivolol 5 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with primary forms of autonomic failure and supine hypertension</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants who were randomized to receive placebo, metoprolol, sildenafil and nebivolol in any order</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.6" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of disease</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Pure autonomic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parkinson Disease with autonomic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple System Atrophy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical history of essential hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic BP, supine</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic BP, upright</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart rate, supine</title>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart rate, upright</title>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma norepinephrine, supine</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136" spread="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma norepinephrine, upright</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="253" spread="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure During the Night</title>
        <description>Maximal change from baseline in systolic blood pressure, measured from 8 pm to 8 am, after a single dose of the intervention</description>
        <time_frame>8 pm - 8 am</time_frame>
        <population>Participants who completed the 4 treatment arms</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>Nebivolol 5 mg</title>
            <description>Nebivolol 5 mg capsule
Nebivolol 5 mg: Nebivolol 5mg single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Metoprolol Tartrate 50 mg</title>
            <description>Metoprolol tartrate 50 mg single oral dose
metoprolol tartrate 50 mg: metoprolol tartrate 50 mg single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Sildenafil 25 mg</title>
            <description>Sildenafil 25 mg single oral dose
Sildenafil25 mg: Sildenafil 25 mg single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure During the Night</title>
          <description>Maximal change from baseline in systolic blood pressure, measured from 8 pm to 8 am, after a single dose of the intervention</description>
          <population>Participants who completed the 4 treatment arms</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline supine at 8 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154" spread="7"/>
                    <measurement group_id="O2" value="162" spread="5"/>
                    <measurement group_id="O3" value="157" spread="5"/>
                    <measurement group_id="O4" value="158" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in systolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="7"/>
                    <measurement group_id="O2" value="-24" spread="9"/>
                    <measurement group_id="O3" value="-7" spread="6"/>
                    <measurement group_id="O4" value="-20" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main comparisons were between the active treatment groups versus placebo. We hypothesized that if NO-mediated vasodilation contributes to the BP-lowering effect of nebivolol then BP will be lowered by nebivolol and sildenafil, but not by metoprolol in autonomic failure patients.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The main comparisons were between the active treatment groups versus placebo. We hypothesized that if NO-mediated vasodilation contributes to the BP-lowering effect of nebivolol then BP will be lowered by nebivolol and sildenafil, but not by metoprolol in autonomic failure patients.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The main comparisons were between the active treatment groups versus placebo. We hypothesized that if NO-mediated vasodilation contributes to the BP-lowering effect of nebivolol then BP will be lowered by nebivolol and sildenafil, but not by metoprolol in autonomic failure patients.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nocturnal Urinary Sodium Excretion</title>
        <description>Nocturnal sodium excretion was defined as the ratio of urinary sodium to urinary creatinine.</description>
        <time_frame>8 pm - 8 am</time_frame>
        <population>Participants with complete urine collections during the 4 study nights</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>Nebivolol 5 mg</title>
            <description>Nebivolol 5 mg capsule
Nebivolol 5 mg: Nebivolol 5mg single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Metoprolol Tartrate 50 mg</title>
            <description>Metoprolol tartrate 50 mg single oral dose
metoprolol tartrate 50 mg: metoprolol tartrate 50 mg single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Sildenafil 25 mg</title>
            <description>Sildenafil 25 mg single oral dose
Sildenafil25 mg: Sildenafil 25 mg single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Nocturnal Urinary Sodium Excretion</title>
          <description>Nocturnal sodium excretion was defined as the ratio of urinary sodium to urinary creatinine.</description>
          <population>Participants with complete urine collections during the 4 study nights</population>
          <units>mEq/mg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.145" spread="0.015"/>
                    <measurement group_id="O2" value="0.127" spread="0.011"/>
                    <measurement group_id="O3" value="0.139" spread="0.019"/>
                    <measurement group_id="O4" value="0.125" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The main comparisons were between the active treatment groups versus placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.607</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Orthostatic Tolerance the Following Morning</title>
        <description>Orthostatic tolerance was defined as the area under the curve of standing systolic blood pressure calculated by the trapezoidal rule (upright systolic blood pressure multiplied by standing time) during a 10-minute standing test</description>
        <time_frame>10 min standing</time_frame>
        <population>Comparisons were made only for patients who could stand after all treatment groups</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>Nebivolol 5 mg</title>
            <description>Nebivolol 5 mg capsule
Nebivolol 5 mg: Nebivolol 5mg single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Metoprolol Tartrate 50 mg</title>
            <description>Metoprolol tartrate 50 mg single oral dose
metoprolol tartrate 50 mg: metoprolol tartrate 50 mg single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Sildenafil 25 mg</title>
            <description>Sildenafil 25 mg single oral dose
Sildenafil25 mg: Sildenafil 25 mg single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Orthostatic Tolerance the Following Morning</title>
          <description>Orthostatic tolerance was defined as the area under the curve of standing systolic blood pressure calculated by the trapezoidal rule (upright systolic blood pressure multiplied by standing time) during a 10-minute standing test</description>
          <population>Comparisons were made only for patients who could stand after all treatment groups</population>
          <units>mm Hg*min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="594" spread="108"/>
                    <measurement group_id="O2" value="675" spread="113"/>
                    <measurement group_id="O3" value="696" spread="128"/>
                    <measurement group_id="O4" value="575" spread="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The main comparisons were between the active treatment groups versus placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.597</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heart Rate During the Night</title>
        <description>Change from baseline (8 pm) in heart rate at the time of maximal BP-lowering effect</description>
        <time_frame>8 pm - 8 am</time_frame>
        <population>Participants who completed the 4 treatment arms</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Capsule</title>
            <description>Placebo capsule
Placebo: Placebo capsule</description>
          </group>
          <group group_id="O2">
            <title>Nebivolol 5 mg</title>
            <description>Nebivolol 5 mg capsule
Nebivolol 5 mg: Nebivolol 5mg single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Metoprolol Tartrate 50 mg</title>
            <description>Metoprolol tartrate 50 mg single oral dose
metoprolol tartrate 50 mg: metoprolol tartrate 50 mg single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Sildenafil 25 mg</title>
            <description>Sildenafil 25 mg single oral dose
Sildenafil25 mg: Sildenafil 25 mg single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heart Rate During the Night</title>
          <description>Change from baseline (8 pm) in heart rate at the time of maximal BP-lowering effect</description>
          <population>Participants who completed the 4 treatment arms</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="2"/>
                    <measurement group_id="O2" value="-6" spread="2"/>
                    <measurement group_id="O3" value="-6" spread="2"/>
                    <measurement group_id="O4" value="0" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The main comparisons were between the negative chronotropic effect of nebivolol and metoprolol at the time when BP-lowering effects were maximal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.996</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day for each intervention</time_frame>
      <desc>Safety population included all participants</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Capsule</title>
          <description>Placebo capsule
Placebo: Placebo capsule</description>
        </group>
        <group group_id="E2">
          <title>Nebivolol 5 mg</title>
          <description>Nebivolol 5 mg capsule
Nebivolol 5 mg: Nebivolol 5mg single oral dose</description>
        </group>
        <group group_id="E3">
          <title>Metoprolol Tartrate 50 mg</title>
          <description>Metoprolol tartrate 50 mg single oral dose
metoprolol tartrate 50 mg: metoprolol tartrate 50 mg single oral dose</description>
        </group>
        <group group_id="E4">
          <title>Sildenafil 25 mg</title>
          <description>Sildenafil 25 mg single oral dose
Sildenafil25 mg: Sildenafil 25 mg single oral dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <description>Participant got up on his own to go to the bathroom during the night, partly falling and injuring his right 5th finger (dislocated).</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection and diarrhea</sub_title>
                <description>During study participation, it was found that she had a urinary tract infection (UTI), which contributed to the worsening of hypotension. Subject was taken off the study and treatment for UTI started. She was discharged without further incident.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Italo Biaggioni MD</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-936-3420</phone>
      <email>italo.biaggioni@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

